Several down, a few to go: histamine H₃ receptor ligands making the final push towards the market?

Bibliography

• Haas H, Panula P. The role of histamine and the tuberomamillary nucleus in the nervous system. Nat Rev Neurosci 2003;20(2):121-30
   Google Scholar
• Leurs R, Chazot PL, Shenton FC, Molecular and biochemical pharmacology of the histamine H4 receptor. Br J Pharmacol 2009;157(1):14-23
   PubMed Web of Science ®Google Scholar
• de Esch IJ, Thurmond RL, Jongejan A, Leurs R. The histamine H4 receptor as a new therapeutic target for inflammation. Trends Pharmacol Sci 2005;26(9):462-9
   PubMed Web of Science ®Google Scholar
• Celanire S, Wijtmans M, Talaga P, Keynote review: histamine H3 receptor antagonists reach out for the clinic. Drug Discov Today 2005;10(23-24):1613-27
   PubMed Web of Science ®Google Scholar
• Leurs R, Bakker RA, Timmerman H, de Esch IJ. The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov 2005;4(2):107-20
   PubMed Web of Science ®Google Scholar
• Parsons ME, Ganellin CR. Histamine and its receptors. Br J Pharmacol 2006;147(Suppl 1):S127-35
   PubMedGoogle Scholar
• Hough LB. Genomics meets histamine receptors: new subtypes, new receptors. Mol Pharmacol 2001;59(3):415-19
   PubMed Web of Science ®Google Scholar
• Shimamura T, Shiroishi M, Weyand S, Structure of the human histamine H1 receptor complex with doxepin. Nature 2011;475(7354):65-70
   PubMed Web of Science ®Google Scholar
• Arrang JM, Garbarg M, Schwartz JC. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983;302(5911):832-7
   PubMed Web of Science ®Google Scholar
• Arrang JM, Garbarg M, Lancelot JC, Highly potent and selective ligands for histamine H3-receptors. Nature 1987;327(6118):117-23
   PubMed Web of Science ®Google Scholar
• Schlicker E, Kathmann M. Modulation of in vitro neurotransmission in the CNS and in the retina via H3 heteroreceptors. In: Leurs R, Timmerman H, editors. The histamine H3 receptor; a target for new drugs. Elsevier; Amsterdam, The Netherlands: 1998. p. 13-16
   Google Scholar
• Martinez-Mir MI, Pollard H, Moreau J, Three histamine receptors (H1, H2 and H3) visualized in the brain of human and non-human primates. Brain Res 1990;526(2):322-7
   PubMed Web of Science ®Google Scholar
• Bertraccini G. Functional role of the histamine H3 receptor in peripheral tissues. In: Leurs R, Timmerman H, editors. The histamine H3 receptor; a target for new drugs. Elsevier; Amsterdam, The Netherlands: 1998. p. 59-111
   Google Scholar
• Wijtmans M, Leurs R, de Esch I. Histamine H3 receptor ligands break ground in a remarkable plethora of therapeutic areas. Expert Opin Investig Drugs 2007;16(7):967-85
   PubMed Web of Science ®Google Scholar
• Passani MB, Blandina P. Histamine receptors in the CNS as targets for therapeutic intervention. Trends Pharmacol Sci 2011;32(4):242-9
   PubMed Web of Science ®Google Scholar
• Leurs R, Vischer HF, Wijtmans M, de Esch IJ. En route to new blockbuster anti-histamines: surveying the offspring of the expanding histamine receptor family. Trends Pharmacol Sci 2011;32(4):250-7
   PubMed Web of Science ®Google Scholar
• Lovenberg TW, Roland BL, Wilson SJ, Cloning and functional expression of the human histamine H3 receptor. Mol Pharmacol 1999;55(6):1101-7
   PubMed Web of Science ®Google Scholar
• Smits RA, Leurs R, de Esch IJ. Major advances in the development of histamine H4 receptor ligands. Drug Discov Today 2009;14(15-16):745-53
   PubMed Web of Science ®Google Scholar
• Bongers G, Bakker RA, Leurs R. Molecular aspects of the histamine H3 receptor. Biochem Pharmacol 2007;73(8):1195-204
   PubMed Web of Science ®Google Scholar
• Lovenberg TW, Pyati J, Chang H, Cloning of rat histamine H3 receptor reveals distinct species pharmacological profiles. J Pharmacol Exp Ther 2000;293(3):771-8
   PubMed Web of Science ®Google Scholar
• Chen J, Liu C, Lovenberg TW. Molecular and pharmacological characterization of the mouse histamine H3 receptor. Eur J Pharmacol 2003;467(1-3):57-65
   PubMed Web of Science ®Google Scholar
• Cassar S. Cloning of the guinea pig H3 receptor. Neuroreport 2000;11(12):L3-4
   PubMedGoogle Scholar
• Tardivel-Lacombe J, Rouleau A, Heron A, Cloning and cerebral expression of the guinea pig histamine H3 receptor: evidence for two isoforms. Neuroreport 2000;11(4):755-9
   PubMed Web of Science ®Google Scholar
• Peitsaro N, Sundvik M, Anichtchik OV, Identification of zebrafish histamine H1, H2 and H3 receptors and effects of histaminergic ligands on behavior. Biochem Pharmacol 2007;73(8):1205-14
   PubMed Web of Science ®Google Scholar
• Yao BB, Sharma R, Cassar S, Cloning and pharmacological characterization of the monkey histamine H3 receptor. Eur J Pharmacol 2003;482(1-3):49-60
   PubMed Web of Science ®Google Scholar
• Strakhova MI, Fox GB, Carr TL, Cloning and characterization of the monkey histamine H3 receptor isoforms. Eur J Pharmacol 2008;601(1-3):8-15
   PubMed Web of Science ®Google Scholar
• Hancock AA, Esbenshade TA, Krueger KM, Yao BB. Genetic and pharmacological aspects of histamine H3 receptor heterogeneity. Life Sci 2003;73(24):3043-72
   PubMed Web of Science ®Google Scholar
• Ireland-Denny L, Parihar AS, Miller TR, Species-related pharmacological heterogeneity of histamine H3 receptors. Eur J Pharmacol 2001;433(2-3):141-50
   PubMed Web of Science ®Google Scholar
• Available from: www.ensembl.org [Last accessed 24 August 2011]
   Google Scholar
• Bongers G, Krueger KM, Miller TR, An 80-amino acid deletion in the third intracellular loop of a naturally occurring human histamine H3 isoform confers pharmacological differences and constitutive activity. J Pharmacol Exp Ther 2007;323(3):888-98
   PubMed Web of Science ®Google Scholar
• Wieland K, Bongers G, Yamamoto Y, Constitutive activity of histamine H3 receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H3 antagonists. J Pharmacol Exp Ther 2001;299(3):908-14
   PubMed Web of Science ®Google Scholar
• Morisset S, Rouleau A, Ligneau X, High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature 2000;408(6814):860-4
   PubMed Web of Science ®Google Scholar
• Berlin M, Boyce CW, de Lera Ruiz M. Histamine H3 receptor as a drug discovery target. J Med Chem 2011;54(1):25-53
   Google Scholar
• Brioni JD, Esbenshade TA, Garrison TR, Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease. J Pharmacol Exp Ther 2011;336(1):38-46
   PubMed Web of Science ®Google Scholar
• Gemkow MJ, Davenport AJ, Harich S, The histamine H3 receptor as a therapeutic drug target for CNS disorders. Drug Discov Today 2009;14(9-10):509-15
   PubMed Web of Science ®Google Scholar
• Yang R, Hey JA, Aslanian R, Rizzo CA. Coordination of histamine H3 receptor antagonists with human adrenal cytochrome P450 enzymes. Pharmacology 2002;66(3):128-35
   PubMed Web of Science ®Google Scholar
• Lazewska D, Kiec-Kononowicz K. Recent advances in histamine H3 receptor antagonists/inverse agonists. Expert Opin Ther Patent 2011;20(9):1147-69
   Web of Science ®Google Scholar
• Stark H. Histamine receptors. Biotrend. Review. No.1 11-2007
   Google Scholar
• Schwartz J. The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol 2011;163(4):713-21
   PubMed Web of Science ®Google Scholar
• Ganellin CR, Leurquin F, Piripitsi A, Synthesis of potent non-imidazole histamine H3-receptor antagonists. Arch Pharm (Weinheim) 1998;331(12):395-404
   PubMed Web of Science ®Google Scholar
• Linney ID, Buck IM, Harper EA, Design, synthesis, and structure-activity relationships of novel non-imidazole histamine H3 receptor antagonists. J Med Chem 2000;43(12):2362-70
   PubMed Web of Science ®Google Scholar
• Meier G, Apelt J, Reichert U, Influence of imidazole replacement in different structural classes of histamine H3-receptor antagonists. Eur J Pharm Sci 2001;13(3):249-59
   PubMed Web of Science ®Google Scholar
• Ligneau X, Perrin D, Landais L, BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: preclinical pharmacology. J Pharmacol Exp Ther 2007;320(1):365-75
   PubMed Web of Science ®Google Scholar
• Ligneau X, Landais L, Perrin D, Brain histamine and schizophrenia: potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649. Biochem Pharmacol 2007;73(8):1215-24
   PubMed Web of Science ®Google Scholar
• Burban A, Sadakhom C, Dumoulin D, Modulation of prepulse inhibition and stereotypes in rodents: no evidence for antipsychotic-like properties of histamine H3-receptor inverse agonists. Psychopharmacology (Berl) 2010;210(4):591-604
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT00690274 Study to demonstrate cognitive enhancing effects of BF2.649. [Last accessed 15 June 2011]
   Google Scholar
• Sander K, Kottke T, Stark H. Histamine H3 receptor antagonists go to clinics. Biol Pharm Bull 2008;31(12):2163-81
   PubMed Web of Science ®Google Scholar
• Lin JS, Dauvilliers Y, Arnulf I, An inverse agonist of the histamine H3 receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. Neurobiol Dis 2008;30(1):74-83
   PubMed Web of Science ®Google Scholar
• Anrhulf I. Results of clinical trials of tripolisant in narcolepsy and Parkinson's disease. Eur Neurophychopharmacol 2009;19:S204
   Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT01072968 BF2.649 in patients with obstructive sleep apnea (OSA), still complaining of excessive daytime sleepiness (EDS) and refusing to be treated by continuous positive airway pressure (CPAP) (HAROSAII). [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT01036139 Efficacy and safety of BF2.649 in excessive daytime sleepiness (EDS) in Parkinson's disease (HARPS 1). [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT01066442 Efficacy and safety of BF2.649 in excessive daytime sleepiness (EDS) in Parkinson's disease (HARPS 2) (HARPS2). [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT01067222 Efficacy and safety study of BF2.649 in the treatment of excessive daytime sleepiness in narcolepsy (harmony1). [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT01067235 Efficacy and safety study of BF2.649 and BF2.649 add on Modafinil on cataplexy in patients with narcolespy (harmony II). [Last accessed 15 June 2011]
   Google Scholar
• Nagase T, Mizutani T, Ishikawa S, Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists. J Med Chem 2008;51(15):4780-9
   PubMed Web of Science ®Google Scholar
• Zoethout RW, Iannone R, Bloem BR, The effects of a novel histamine-3 receptor inverse agonist on essential tremor in comparison to stable levels of alcohol. J Psychopharmacol 2011; published online 18 February 2011; doi: 101177/0269881111398685 2011 Feb 24
   Web of Science ®Google Scholar
• Iannone R, Palcza J, Renger JJ, Acute alertness-promoting effects of a novel histamine subtype-3 receptor inverse agonist in healthy sleep-deprived male volunteers. Clin Pharmacol Ther 2010;88(6):831-9
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT00420420 MK0249 for the symptomatic treatment of Alzheimer's disease (MK0249-011) (completed). [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT00475735 A study to test the safety and efficacy of MK0249 in patients with ADHD (0249-018) (completed). [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT00506077 MK0249 for the treatment of cognitive impairment in patients with schizophrenia (0249-016). [Last accessed 15 June 2011]
   Google Scholar
• Egan M, Harper L, Gottwald R, Effects of H3 inverse agonist MK-0249 on cognitive performance in patients with schizophrenia. In ACNP 48th Annual Meeting; 6 – 10 December 2009; Hollywood, FL. American College of Neurophsychophramacology; Nashville, TN
   Google Scholar
• James LM, Iannone R, Palcza J, Effect of a novel histamine subtype-3 receptor inverse agonist and modafinil on EEG power spectra during sleep deprivation and recovery sleep in male volunteers. Psychopharmacology (Berl) 2011;215(4):643-53
   PubMed Web of Science ®Google Scholar
• Le S, Gruner JA, Mathiasen JR, Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists. J Pharmacol Exp Ther 2008;325(3):902-9
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT00620659 Treatment of refractory excessive daytime sleepiness in patients with obstructive sleep apnea/hypopnea syndrome (OSA/HS) using nasal continuous positive airway pressure (nCPAP) therapy (0249-015). [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://www.merck.com/research/pipeline/Merck%20October%202009%20Combined%20Pipeline.pdf [Last accessed 22 May 2011]
   Google Scholar
• Medhurst AD, Atkins AR, Beresford IJ, GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther 2007;321(3):1032-45
   PubMed Web of Science ®Google Scholar
• Armer R, Warne P, Witherington J. Highlights of the Society for Medicines Research Symposium held December 8, 2005, in London, United Kingdom. Discovery of a novel series of potent, orally active histamine H3 receptor antagonists. Drug News Perspect 2006;19(1):67-9
   Google Scholar
• Ashworth S, Rabiner EA, Gunn RN, Evaluation of 11C-GSK189254 as a novel radioligand for the H3 receptor in humans using PET. J Nucl Med 2010;51(7):1021-9
   PubMed Web of Science ®Google Scholar
• Giannoni P, Medhurst AD, Passani MB, Regional differential effects of the novel histamine H3 receptor antagonist 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-p yridinecarboxamide hydrochloride (GSK189254) on histamine release in the central nervous system of freely moving rats. J Pharmacol Exp Ther 2010;332(1):164-72
   PubMed Web of Science ®Google Scholar
• Available from: http://www.gsk.com/investors/reps05/annual-report-2005.pdf [Last accessed 22 May 2011]
   Google Scholar
• Medhurst SJ, Collins SD, Billinton A, Novel histamine H3 receptor antagonists GSK189254 and GSK334429 are efficacious in surgically-induced and virally-induced rat models of neuropathic pain. Pain 2008;138(1):61-9
   PubMed Web of Science ®Google Scholar
• Hsieh GC, Honore P, Pai M, Antinociceptive effects of histamine H3 receptor antagonist in the preclinical models of pain in rats and the involvement of central noradrenergic systems. Brain Res 2010;1354:74-84
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT00387413 A study of GSK189254 and duloxetine in the electrical hyperalgesia model of healthy volunteers. [Last accessed 15 June 2011]
   Google Scholar
• Guo RX, Anaclet C, Roberts JC, Differential effects of acute and repeat dosing with the H3 antagonist GSK189254 on the sleep-wake cycle and narcoleptic episodes in Ox-/- mice. Br J Pharmacol 2009;157(1):104-17
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT00366080 Effectiveness of the drug GSK189254 in treating patients with narcolepsy. [Last accessed 15 June 2011]
   Google Scholar
• Available from: www.gsk.com/investors/reps08/GSK-Report-2008-full.pdf [Last accessed 22 May 2011]
   Google Scholar
• Letavic MA, Aluisio L, Atack JR, Pre-clinical characterization of aryloxypyridine amides as histamine H3 receptor antagonists: identification of candidates for clinical development. Bioorg Med Chem Lett 2010;20(14):4210-14
   PubMed Web of Science ®Google Scholar
• Galici R, Rezvani AH, Aluisio L, JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats. Psychopharmacology (Berl) 2011;214(4):829-41
   PubMed Web of Science ®Google Scholar
• Pippel DJ, Mills JE, Pandit CR, First, second and third generation scalable syntheses of two potent H3 antagonists. Org Process Res Dev 2011;15(3):638-48
   Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT00804687 Safety and efficacy of JNJ-39220675 in participants with allergic rhinitis. [Last accessed 15 June 2011]
   Google Scholar
• Varty LM, Gustafson E, Laverty M, Hey JA. Activation of histamine H3 receptors in human nasal mucosa inhibits sympathetic vasoconstriction. Eur J Pharmacol 2004;484(1):83-9
   PubMed Web of Science ®Google Scholar
• Carruthers NI. Translational approaches towards the identification of a histamine H3 receptor antagonist and its' clinical evaluation for the symptomatic treatment of allergic rhinitis. Abstracts of the 39th Annual Meeting of the European Histamine Research Society; 13 – 16 July 2010; Durham, United Kingdom. Inflamm Res 2010;59(Suppl 4):S339
   Google Scholar
• Panula P, Nuutinen S. Histamine and H3 receptor in alcohol-related behaviors. J Pharmacol Exp Ther 2011;336(1):9-16
   PubMed Web of Science ®Google Scholar
• Schmidt AW, Butler T, Chandrasekaran R, PF-03654746: A potent and selective histamine H3 receptor antagonist. 734.5/L23 2009 Neuroscience Meeting Planner; Society for Neuroscience; Chicago, IL; 2009
   Google Scholar
• Soares H, Wager TT, Schmidt AW, H3 receptor antagonism increases methylhistamine levels in the cerebrospinal fluid of dogs and healthy human volunteers. Alzheimers Demen 2009;5:P254-5
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT00730990 A phase I, healthy volunteer positron emission tomography study. [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT01346163 Add on treatment for cognitive deficits in schizophrenia. [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT00531752 A study to evaluate the efficacy and safety of two doses of PF-03654746 in adults with attention deficit hyperactivity disorder (ADHD). [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://www.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf [Last accessed 22 May 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT01028911 A study to evaluate the safety, tolerability, and blood levels of PF-03654746 in subjects with mild to moderate Alzheimer's disease. [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://www.pfizer.com/files/research/pipeline/2010_0927/pipeline_2010_0927.pdf [Last accessed 22 May 2011]
   Google Scholar
• Available from: http://www.pfizer.com/files/research/pipeline/2011_0228/pipeline_2011_0228.pdf [Last accessed 22 May 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT01006122 A study of a novel compound for excessive daytime sleepiness associated with narcolepsy. [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT00562120 A study to test a new decongestant in patients with allergic rhinitis following a nasal allergen challenge. [Last accessed 15 June 2011]
   Google Scholar
• Romero FA Jr, Allan RJ, Phillips PG, The effects of an H3 receptor antagonist in a nasal allergen challenge model. J Allery Clin Immunol 2010;125:AB191
   Google Scholar
• Available from: http://www.ama-assn.org/resources/doc/usan/bavisant.pdf [Last accessed 24 August 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT00915746 A drug interaction study of JNJ-31001074 and ketoconazole in healthy volunteers. [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT01159821 A drug interaction study of 31001074 and paroxetine in healthy volunteers. [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT00915668 A study to evaluate the pharmacokinetic drug interaction between multiple doses of JNJ-31001074 and a single dose of an oral contraceptive containing ethinyl estradiol and levonorgestrel in women. [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT00915434 A study to characterize the pharmacokinetics and effect of food on JNJ-31001074 in healthy volunteers. [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT00890240 A study to evaluate pharmacokinetics, safety and tolerability after a single dose administration of of JNJ-31001074 in children (6-11 years) with attention deficit hyperactivity disorder (ADHD). [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT00890292 A study to evaluate pharmacokinetics, safety and tolerability after a single dose administration of JNJ-31001074 in pediatric patients (12-17 years) with attention deficit hyperactivity disorder (ADHD). [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT00566449 A safety and effectiveness study of JNJ-31001074 in adults with attention-deficit/hyperactivity disorder. [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT00880217 A study to evaluate 3 different doses of JNJ-31001074 in the treatment of adults with attention-deficit/hyperactivity disorder (ADHD). [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT01362699 Study of the efficacy of JNJ 31001074 on cue induced craving for alcohol. [Last accessed 15 June 2011]
   Google Scholar
• Cowart MD, Esbenshade AT, Browman KE, Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3-receptor antagonist. Inflamm Res 2010;59(Suppl 4):S305-59
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT00888693 A multiple dose study of safety, tolerability, pharmacokinetics, and pharmacodynamics of ABT-288 in stable subjects with schizophrenia. [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT01077700 Efficacy and safety study for cognitive deficits in adult subjects with schizophrenia. [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT01018875 Efficacy and safety study of ABT-288 in subjects with mild-to-moderate Alzheimer's disease. [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://download.gsk-clinicalstudyregister.com/files/54aec5ef-45f3-492c-9e2d-ee823ef493af [Last accessed 22 May 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT00474513 An imaging study to investigate the distribution of GSK239512 in the brain. [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT00675090 Bridging study with GSK239512 in patients with mild to moderate Alzheimer's disease. [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT01009255 Study to evaluate the efficacy and safety of GSK239512 in Alzheimer's disease. [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT01009060 Study to evaluate the efficacy and safety of GSK239512 in schizophrenia. [Last accessed 15 June 2011]
   Google Scholar
• Guillot E, Pichat P, Griebel G, SAR110894, a novel, potent and selective H3-receptor (H3-R) antagonists: I. binding and functional characterization. 160.21/FF6. 2008 Neuroscience Meeting Planner. Society for Neuroscience; Washington, DC; 2008
   Google Scholar
• Pichat P, Boulay D, Terranova J-P, SAR110894, a novel, potent and selective H3-receptor (H3-R) antagonists: II. effects in models predictive for therapeutic activity against cognitive and addention deficits in schizophrenia and ADHD. 160.20/FF5. 2008 Neuroscience Meeting Planner. Society for Neuroscience; Washington, DC; 2008
   Google Scholar
• Black M, Pichat P, Weiner I, SAR110894, a novel, potent and selective H3-receptor (H3-R) antagonists: III. Potential activity in positive symptom and cognitive domains of schizophrenia using latent inhibition (LI) models in the rat. 160.19/FF4. 2008 Neuroscience Meeting Planner. Society for Neuroscience; Washington, DC; 2008
   Google Scholar
• Available from: http://en.sanofi.com/binaries/070917_PDF_Slides_media_1_tcm28-15741.pdf [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT01266525 Effect of different doses of SAR110894D on cognition in patients with mild to moderate Alzheimer's disease on Donepezil. [Last accessed 15 June 2011]
   Google Scholar
• Schneider JS, Decamp E, Hill M, Effects of the novel histamine H3 receptor antagonist S 38093 in a non-human primate model of cognitive dysfunction [abstract P4-342]. 12th International Conference Alzheimer's related diseases. Vienna; 2009
   Google Scholar
• Available from: http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=5282 [Last accessed 22 May 2011]
   Google Scholar
• Available from: http://oss-sper-clin.agenziafarmaco.it/cgi-bin/ossc_view_pub?CODICE_PROT=CL2-38093-009&TITOLO_PROT=&FILE=scheda_part_pub&AZIONEFORM=VIEW&ID_SPER=46877& [Last accessed 22 May 2011]
   Google Scholar
• Available from: http://www.taylorwessing.com/uploads/tx_siruplawyermanagement/scrip_rehmann_morgan.pdf [Last accessed 22 May 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT00673465 Effect of SCH 497079 on metabolic parameters and influence of race/ethnic origin on therapeutic response (study P05338AM1)(completed). [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT00642993 Efficacy and safety trial to evaluate the effect of SCH 497079 on weight in obese and overweight subjects (study P05483)(completed). [Last accessed 15 June 2011]
   Google Scholar
• Chemical & Engineering News, 89(16) page 37, April 18, 2011
   Google Scholar
• Hudkins RL, Raddatz R, Tao M, Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, Irdabisant): a potent, selective histamine H3 receptor inverse agonist. J Med Chem 2011; published online 2 June 2011; doi: 101021/jm200401v 2011 Jun 2
   Web of Science ®Google Scholar
• Hudkins RL, Raddatz R, Tao M, Discovery and characterization of CEP-26401: A potent, selective histamine H3 receptor inverse agonist. 241st ACS National Meeting & Exposition; 27 – 31 March 2011; Anaheim, California
   Google Scholar
• Available from: http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9Mzc1MTkwfENoaWxkSUQ9MzczNTM5fFR5cGU9MQ==&t=1 [Last accessed 24 August 2011]
   Google Scholar
• Hudkins RL, Aimone LD, Bailey TR, Identification of pyridazin-3-one derivatives as potent, selective histamine H(3) receptor inverse agonists with robust wake activity. Bioorg Med Chem Lett published online 30 June 2011; doi: 101016/jbmcl201106108 2011 Jun 30
   Google Scholar
• Grottick AJ, Barrera G, Edwards J, Characterization of APD916, a novel histamine H3 antagonist with wake promoting properties. 285.4/QQ20. 2008 Neuroscience Meeting Planner. Society for Neuroscience; Washingtion, DC; 2008
   Google Scholar
• Available from: http://files.shareholder.com/downloads/ARNA/1233974285x0x410899/ede6e0ff-a34e-4372-8fbf-1c8b00d6e161/ARNA_News_2010_10_20_General.pdf [Last accessed 22 May 2011]
   Google Scholar
• Available from: http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&blobheader=application%2Fpdf&blobheadername1=Content-Disposition&blobheadername2=MDT-Type&blobheadervalue1=inline%3B+filename%3DDownload-pipeline-summary.pdf&blobheadervalue2=abinary%3B+charset%3DUTF-8&blobkey=id&blobtable=MungoBlobs&blobwhere=1285619440126&ssbinary=true [Last accessed 22 May 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT01121302 Study to investigate single ascending oral doses of AZD5213 in healthy male and non fertile female subjects. [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT01171105 Study to investigate multiple ascending oral doses of AZD5213 in healthy male and non fertile female subjects. [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT01335451 Assess the safety, tolerability and pharmacokinetics of AZD5213 after single and multiple ascending oral doses in healthy young and elderly Japanese subjects. [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://clinicaltrials.gov; Identifier: NCT01194986 Evaluation of histamine H3 receptor radioligand [11C]AZ12807110 and histamine H3 receptor occupancy of AZD5213 after oral administration. [Last accessed 15 June 2011]
   Google Scholar
• Available from: http://www.ttpharma.com/TherapeuticAreas/MetabolicDiseases/Obesity/HPP404/tabid/128/Default.aspx [Last accessed 22 May 2011]
   Google Scholar
• Aslanian R, Mutahi M, Shih NY, Identification of a dual histamine H1/H3 receptor ligand based on the H1 antagonist chlorpheniramine. Bioorg Med Chem Lett 2003;13(12):1959-61
   PubMed Web of Science ®Google Scholar
• Norman P. New H1/H3 antagonists for treating allergic rhinitis: WO2010094643. Expert Opin Ther Patent 2011;21(3):425-9
   PubMed Web of Science ®Google Scholar
• Procopiou PA, Browning C, Buckley JM, The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis. J Med Chem 2011;54(7):2183-95
   PubMed Web of Science ®Google Scholar
• Clark K, Russell L, Hall D, Preclinical pharmacology of the novel intranasal dual histamine H1 and H3 receptor antagonist GSK1004723. Allergy 2009;64(S90):129
   Google Scholar
• Slack RJ, Russell LJ, Hall DA, Pharmacological characterisation of GSK1004723, a novel, long acting antagonist at histamine H1 and H3 receptors. Br J Pharmacol 2011; published online 24 February 2011; doi: 101111/j1476-5381201101285x 2011
   PubMed Web of Science ®Google Scholar
• Available from: https://pharmainpartnership.gsk.com/Account/Datasheet.aspx/44350182 [Last accessed 22 May 2011]
   Google Scholar
• Ford A, Browning C, Russell L, Preclinical pharmacology of the novel oral dual histamine H1 and H3 receptor antagonist GSK835726. Allergy 2009;64(S90):69
   Google Scholar
• Black LA, Nersesian DL, Sharma P, 4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration. Bioorg Med Chem Lett 2007;17(5):1443-6
   PubMed Web of Science ®Google Scholar
• Procopiou PA, Ancliff RA, Bamford MJ, 4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists. J Med Chem 2007;50(26):6706-17
   PubMed Web of Science ®Google Scholar